1. Introduction {#sec1}
===============

Cholangiocarcinoma (CCA) is the second most frequent type of primary liver cancer, with aggressive nature and a high mortality rate, accounting for 20% of liver-related deaths \[[@B1]\]. The incidence of CCA is increasing during the past decades in Western countries, and the 5-year survival rate is approximately 10% \[[@B2], [@B3]\]. Surgical resection is the definitive treatment option for CCA; however, recurrence remains high and maintains a poor prognosis \[[@B4], [@B5]\]. Emerging treatment options, including targeted therapies and immunotherapy with checkpoint inhibitors, are in clinical trials and provide personalized therapeutic strategies for patients with CCA \[[@B5]\]. Efficient prognostic biomarkers are still lacking for CCA; therefore, a reliable prognostic marker is needed for optimal therapeutic strategy selection \[[@B6]\].

In recent years, the tumor microenvironment and immune milieu have attracted much attention \[[@B7]\]. The immune checkpoint molecules, programmed cell death-1 (PD-1) and its ligand programmed death-ligand-1 (PD-L1), regulate immune responses in cancer development \[[@B8]\]. Activation of the PD-1/PD-L1 axis results in immune suppression by inhibition of immune cells and secretion of certain cytokines \[[@B9]\]. Recent evidence also showed the prognostic value of PD-L1 in different types of cancers \[[@B10]\]. The prognostic role of PD-L1 in CCA has also been investigated; however, data were inconsistent \[[@B11]--[@B28]\]. Therefore, we conducted a meta-analysis to explore the prognostic and clinicopathologic roles of PD-L1 in patients with CCA.

2. Materials and Methods {#sec2}
========================

This meta-analysis was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement \[[@B29]\]. Ethical approval and patient consent were not performed because all data collected were from previously published studies.

2.1. Literature Search {#sec2.1}
----------------------

PubMed, Web of Science, Cochrane Library, and Embase were reviewed till April 17, 2020. The search terms used were "PD-L1" or "programmed death ligand 1" or "PDL1" or "B7-H1" or "CD274", and "bile duct neoplasms" or "cholangiocarcinoma" or "bile duct cancer". The reference lists in relevant studies were also examined for potential inclusions.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

The criteria for inclusion were (1) patients histologically diagnosed with CCA; (2) PD-L1 expression detected by immunohistochemistry (IHC); (3) studies reporting the relationship between PD-L1 and survival outcomes including overall survival (OS) and disease-free survival (DFS); (4) sufficient data available for the calculation of hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs); and (5) studies published in English.

The exclusion criteria were (1) conference abstracts, case reports, reviews, or letters; (2) studies with insufficient data for analysis; (3) animal studies; and (4) studies recruited overlapping patients.

2.3. Data Extraction {#sec2.3}
--------------------

Two independent investigators (Q.X. and L.W.) collected data from the included studies and any discrepancies were settled by discussion with a senior investigator (S.Z.). The following baseline information was extracted: author, year, study country, study design, sample size, treatment method, follow-up, survival outcomes, positive rate of PD-L1 expression, and detection method. Detailed information on PD-L1 antibodies used for IHC (specie, clone, dilution, source, and cutoff value) was also extracted. The HR and 95% CIs of OS and DFS were obtained directly if reported or were calculated by Tierney\'s method \[[@B30]\].

2.4. Quality Assessment {#sec2.4}
-----------------------

The Newcastle-Ottawa Scale (NOS) was applied to evaluate the quality of eligible studies \[[@B31]\]. The NOS evaluated each study in three aspects. The score ranges from 0-9, and studies with NOS scores of ≥6 are considered high-quality studies.

2.5. Statistical Analysis {#sec2.5}
-------------------------

The relationships between PD-L1, OS, and DFS were assessed by combining HRs and 95% CIs. Chi-squared tests and inconsistency index (*I*^2^) statistics were used to examine heterogeneity. In the presence of significant heterogeneity (*I*^2^ \> 50%), a random-effect (REM) model was used; otherwise, a fixed-effect model (FEM) was applied. ORs and 95% CIs were used as effective sizes to assess the association between PD-L1 and clinicopathological features. Publication bias was tested using Begg\'s and Egger\'s tests. A *p* \< 0.05 was considered to be statistically significant. All statistical analyses were conducted using Stata version 12.0 (StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP.).

3. Results {#sec3}
==========

3.1. Study Characteristics {#sec3.1}
--------------------------

The initial literature search identified 259 studies. According to the selection criteria, a total of 18 studies \[[@B11]--[@B28]\] with 2012 patients were eventually included in the meta-analysis ([Figure 1](#fig1){ref-type="fig"}). The basic characteristics of the eligible studies are shown in [Table 1](#tab1){ref-type="table"}. Seven studies were conducted in China \[[@B13], [@B15], [@B16], [@B21], [@B22], [@B27], [@B28]\], three in Japan \[[@B18], [@B24], [@B25]\], two in Korea \[[@B11], [@B20]\], two in Germany \[[@B19], [@B26]\], two in Germany \[[@B14], [@B17]\], and one in Thailand \[[@B23]\] and UK \[[@B12]\]. One study was of prospective design \[[@B12]\], and 17 were retrospective cohort studies \[[@B11], [@B13]--[@B28]\]. The sample size ranged from 26 to 320. All included studies had a NOS score of ≥6. Detailed information on the primary antibody used for PD-L1 is summarized in [Table 2](#tab2){ref-type="table"}. All included studies used IHC to detect PD-L1 expression. The cutoff values to stratify high- and low expression of PD-L1 were different, including 1%, 5%, H-score 5, score 3, and 2+.

3.2. Prognostic Value of PD-L1 in OS, DFS, and Subgroup Analysis {#sec3.2}
----------------------------------------------------------------

Seventeen studies \[[@B11]--[@B14], [@B16]--[@B28]\] with a total of 1982 patients reported a correlation between PD-L1 and OS. The pooled HR and 95% CI suggested that overexpression of PD-L1 was significantly correlated with worse OS (HR = 1.58, 95%CI = 1.30 − 1.92, p \< 0.001) in patients with CCA ([Figure 2](#fig2){ref-type="fig"}; [Table 3](#tab3){ref-type="table"}). For DFS, a total of 7 studies \[[@B11], [@B12], [@B15], [@B20], [@B21], [@B27], [@B28]\] with 896 patients provided the relevant data. The forest plot ([Figure 3](#fig3){ref-type="fig"}) showed that PD-L1 expression was not significantly correlated with DFS (HR = 1.03, 95%CI = 0.68 − 1.55, *p* = 0.895) ([Table 3](#tab3){ref-type="table"}). To further investigate the source of heterogeneity, subgroup analysis stratified by ethnicity (Caucasian and Asian), tumor location (iCCA, eCCA, and CCA), and treatment (surgery and nonsurgery) was performed for OS and DFS. For OS, PD-L1 overexpression remained a prognostic factor for patients of Caucasian (HR = 2.14, 95%CI = 1.52 − 3.02, *p* \< 0.001) and Asian (HR = 1.49, 95%CI = 1.20 − 1.84, *p* \< 0.001) ethnicity; and for those receiving surgery (HR = 1.61, 95%CI = 1.32 − 1.95, *p* \< 0.001) ([Table 3](#tab3){ref-type="table"}). Notably, regarding tumor location, high PD-L1 expression was a prognostic factor for patients with eCCA (HR = 1.71, 95%CI = 1.25 − 2.36, *p* \< 0.001) and CCA including iCCA and eCCA (HR = 1.98, 95%CI = 1.47 − 2.65, *p* \< 0.001). However, elevated PD-L1 expression did not correlate with worse OS in patients with iCCA (HR = 1.31, 95%CI = 0.88 − 1.95, *p* = 0.180) ([Table 3](#tab3){ref-type="table"}). For DFS, the subgroup analysis indicated that PD-L1 overexpression had no significant prognostic value regardless of ethnicity, treatment method, or tumor location ([Table 3](#tab3){ref-type="table"}).

3.3. PD-L1 and Clinicopathological Characteristics of CCA {#sec3.3}
---------------------------------------------------------

Thirteen studies \[[@B11], [@B13], [@B16], [@B18], [@B19], [@B21]--[@B28]\] investigated the relationship between PD-L1 and the following eight clinicopathological factors: sex (male vs. female), tumor differentiation (poor vs. well/moderate), pN stage (III+IV vs. I+II), TNM stage (III+IV vs. I+II), vascular invasion (yes vs. no), perineural invasion (yes vs. no), age (\>60 vs. ≤60), and tumor size (\>5 cm vs. ≤5 cm). As shown in [Figure 4](#fig4){ref-type="fig"}, high PD-L1 expression was correlated with poor differentiation (OR = 1.43, 95%CI = 1.09 − 1.87, *p* = 0.010) and higher pN stage (OR = 1.45, 95%CI = 1.10 − 1.92, *p* = 0.009). However, no significant correlation was found between PD-L1 and sex (OR = 1.23, 95%CI = 0.95 − 1.58, *p* = 0.114), TNM stage (OR = 1.42, 95%CI = 0.83 − 2.45, *p* = 0.204), vascular invasion (OR = 1.28, 95%CI = 0.69 − 2.38, *p* = 0.431), perineural invasion (OR = 1.00, 95%CI = 0.59 − 1.68, *p* = 0.994), age (OR = 0.90, 95%CI = 0.61 − 1.33, *p* = 0.609), and tumor size (OR = 0.97, 95%CI = 0.70 − 1.33, *p* = 0.828).

3.4. Publication Bias {#sec3.4}
---------------------

Begg\'s funnel plot and Egger\'s tests were applied to evaluate the publication bias in this meta-analysis. There was no obvious publication bias for OS (Begg\'s test of *p* = 0.902, Egger\'s test of *p* = 0.670) or DFS (Begg\'s test of *p* = 0.230, Egger\'s test of *p* = 0.266).

4. Discussion {#sec4}
=============

CCA is an aggressive cancer, and most patients present at an advanced stage at the time of diagnosis \[[@B32], [@B33]\]. The current meta-analysis containing 18 studies with 2012 patients showed that high PD-L1 expression was a significant prognostic factor for low OS (HR = 1.58). Particularly, the mortality risk of patients with CCA with high PD-L1 expression increased by 58% compared with that of patients with low PD-L1 expression. PD-L1 expression was not significantly correlated with DFS. In addition, we found that PD-L1 was positively associated with poor differentiation and higher pN stage in CCA. Generally, these results demonstrated that PD-L1 overexpression was associated with invasive clinical features and suggested poorer prognosis of CCA.

The tumor microenvironment in CCA consists of cancer cells, stromal cells, and various immune cells including CCA cells, cancer-associated fibroblasts, tumor-associated macrophages, tumor-infiltrating lymphocytes, and CD8+ cytotoxic T lymphocytes \[[@B34]\]. PD-1 is expressed on B cells, activated CD4+ and CD8+ T cells, and dendritic cells \[[@B35]\]. PD-L1 is a ligand of PD-1 and is expressed on different cell types \[[@B36]\]. Targeting PD-1/PD-L1 is a new strategy for cancer immunotherapy \[[@B37]\]. Recent studies showed that nivolumab (a PD-1 inhibitor) showed considerable safety in patients with metastatic CCA \[[@B15]\]. PD-L1 is mainly expressed by intertumoral immune cells in CCA \[[@B38]\]. Thus, the overexpression of PD-L1 may lead to immune tolerance in the tumor environment and result in tumor progression. This could be a possible mechanism for the correlation between PD-L1 elevation and poor differentiation in CCA.

Recent studies have demonstrated that PD-L1 overexpression is associated with unfavorable prognosis in various types of cancer \[[@B39], [@B40]\]. A recent meta-analysis showed that high expression of PD-L1 was significantly associated with a poor OS (HR = 1.22, 95%CI = 1.01 − 1.48, *p* = 0.04) in colorectal cancer \[[@B41]\]. Another meta-analysis including 13 studies also demonstrated that tumor cell PD-L1 expression was correlated with poor OS (HR = 2.128, 95%CI : 1.341--3.378, *p* = 0.001) in patients with diffuse large B-cell lymphoma \[[@B42]\]. These findings were consistent with the results of this study. Notably, in the current meta-analysis, we included studies using the IHC method to detect PD-L1. The antibodies used for PD-L1 and cutoff values vary among the included studies, which may result in heterogeneity. However, we failed to observe a significant prognostic role of PD-L1 in DFS in patients with CCA. This negative result may be due to the limited sample size, wherein only 7 studies with 896 patients were included for DFS analysis.

Notably, several limitations of this study should be acknowledged. First, the cutoff values of PD-L1 varied in the included studies ([Table 2](#tab2){ref-type="table"}), which may introduce heterogeneity. Further investigations used uniform antibody and a cut-off value of PD-L1 are needed. Second, only one included study was a prospective trial, and the remaining were retrospective studies. Therefore, high-quality prospective studies are still needed. Third, some HRs and 95% CIs were calculated according to survival curves, which may not be as precise as the original data. Fourth, the sample was relatively small. Only 2012 patients were enrolled and most patients were of Asian ethnicity. More studies recruiting patients of diverse ethnicities were needed to verify the results of this meta-analysis. Because of these limitations, well-designed large cohort studies or randomized controlled trials may be recommended to confirm our findings.

5. Conclusions {#sec5}
==============

Our study indicates that PD-L1 was associated with worse OS, poor differentiation, and higher pN stage in patients with CCA. PD-L1 could be a potential prognostic marker for CCA.
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###### 

Characteristics of the studies included in the meta-analysis.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author             Year   Country    No. of patients   Ethnicity   Sex (M/F)   Tumor location   Follow-up (months)\   Study design    Treatment                          Survival outcome   PD-L1 (+)\   NOS score
                                                                                                  Median (range)                                                                              *n* (%)      
  ------------------ ------ ---------- ----------------- ----------- ----------- ---------------- --------------------- --------------- ---------------------------------- ------------------ ------------ -----------
  Ahn, S.            2019   Korea      183               Asian       122/61      eCCA             27.2                  Retrospective   Surgery                            OS, DFS            31 (16.9)    7

  Arkenau, H. T.     2018   UK         26                Caucasian   8/18        CCA              6.4 (4.1-13.2)        Prospective     Targeted therapy + immunotherapy   OS, DFS            12 (46.2)    8

  Dong, Z. T.        2020   China      125               Asian       58/77       iCCA             16 (5-63)             Retrospective   Surgery                            OS, DFS            52 (41.6)    7

  Gani, F.           2016   USA        54                Caucasian   17/37       iCCA             NR                    Retrospective   Surgery                            OS                 39 (72.2)    6

  Gou, M. M.         2019   China      30                Asian       18/12       CCA              To Sep 2018           Retrospective   Immunotherapy                      DFS                11 (36.6)    7

  Jing, C. Y.        2019   China      153               Asian       NR          iCCA             47.5 (1-88.4)         Retrospective   Surgery                            OS                 43 (28.1)    7

  Kim, R.            2018   USA        44                Caucasian   23/21       eCCA             NR                    Retrospective   Surgery                            OS                 10 (22.7)    6

  Kitano, Y.         2020   Japan      177               Asian       115/62      CCA              78.7                  Retrospective   Surgery                            OS                 54 (30.5)    6

  Kriegsmann, M.     2019   Germany    170               Caucasian   109/61      CCA              NR                    Retrospective   Surgery                            OS                 19 (11.1)    6

  Lim, Y. J.         2015   Korea      83                Asian       61/22       eCCA             27                    Retrospective   Surgery                            OS, DFS            56 (83)      7

  Lu, J. C.          2019   China      320               Asian       19/129      iCCA             To Oct 2016           Retrospective   Surgery                            OS, DFS            99 (30.9)    7

  Ma, K.             2017   China      70                Asian       38/32       eCCA             To Mar 2015           Retrospective   Surgery                            OS                 30 (42.9)    7

  Sangkhamanon, S.   2017   Thailand   46                Asian       33/13       CCA              NR                    Retrospective   Surgery                            OS                 18 (39.1)    6

  Tamai, K.          2014   Japan      91                Asian       62/29       eCCA             NR                    Retrospective   Surgery                            OS                 77 (84.6)    6

  Ueno, T.           2018   Japan      117               Asian       93/24       eCCA             27 (0-189)            Retrospective   Surgery                            OS                 10 (8.5)     7

  Walter, D.         2017   Germany    69                Caucasian   50/19       eCCA             23 (0-100)            Retrospective   Surgery                            OS                 8 (11.6)     7

  Yu, F.             2019   China      62                Asian       41/21       eCCA             NR                    Retrospective   Surgery                            OS, DFS            20 (32.3)    6

  Zhu, Y.            2018   China      192               Asian       115/77      iCCA             24 (0.4-85)           Retrospective   Surgery                            OS, DFS            34 (17.7)    7
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CCA: cholangiocarcinoma; eCCA: extrahepatic cholangiocarcinoma; iCCA: intrahepatic cholangiocarcinoma; NR: not reported; OS: overall survival; DFS: disease-free survival; NOS: Newcastle-Ottawa scale. CCA includes iCCA and eCCA.

###### 

Immunohistochemical technique used in the studies included in the meta-analysis.

  Author             Year   Detection method   Primary antibody   Source        Cut-off value                                                                 
  ------------------ ------ ------------------ ------------------ ------------- --------------- ---------- -------------------------------------------------- -----------
  Ahn, S.            2019   IHC                Anti-PD-L1         Mouse, MAB    22C3            1 : 100    Dako, Carpinteria, CA, USA                         1%
  Arkenau, H. T.     2018   IHC                Anti-PD-L1         Mouse, MAB    22C3            NR         Agilent, Carpinteria, CA                           1%
  Dong, Z. T.        2020   IHC                Anti-PD-L1         MAB           NR              NR         Cell Signaling Technology, Inc. Danvers, MA, USA   5%
  Gani, F.           2016   IHC                Anti-PD-L1         Mouse, MAB    5H1             NR         NR                                                 5%
  Gou, M. M.         2019   IHC                Anti-PD-L1         NR            NR              NR         NR                                                 1%
  Jing, C. Y.        2019   IHC                Anti-PD-L1         Rabbit, MAB   E1L3N           1 : 200    Cell Signaling Technology, MA, USA                 5%
  Kim, R.            2018   IHC                Anti-PD-L1         Mouse, MAB    5H1             NR         NR                                                 1%
  Kitano, Y.         2020   IHC                Anti-PD-L1         Rabbit, MAB   E1L3N           1 : 200    Cell Signaling Technology, Tokyo, Japan            5%
  Kriegsmann, M.     2019   IHC                Anti-PD-L1         NR            SP263           NR         Roche AG, Rotkreuz, Switzerland                    1%
  Lim, Y. J.         2015   IHC                Anti-PD-L1         Rabbit, MAB   E1L3N           1 : 100    Cell Signaling Technology, Danvers, MA, USA        H-score 5
  Lu, J. C.          2019   IHC                Anti-PD-L1         Rabbit, MAB   SP142           1 : 100    GeneTech Co. Ltd., Shanghai, China                 5%
  Ma, K.             2017   IHC                Anti-PD-L1         Rabbit, MAB   NR              1 : 250    Abcam, Cambridge, MA, USA                          5%
  Sangkhamanon, S.   2017   IHC                Anti-PD-L1         NR            NR              1 : 1000   Roche Diagnostic GmbH, USA                         1%
  Tamai, K.          2014   IHC                Anti-CD274         Rabbit, PAB   NR              NR         Abcam, Cambridge, MA, USA                          ++
  Ueno, T.           2018   IHC                Anti-PD-L1         NR            NR              NR         NR                                                 5%
  Walter, D.         2017   IHC                Anti-PD-L1         Rabbit, MAB   E1L3N           1 : 50     Cell Signaling Technology, Danvers, MA, USA        Score 3
  Yu, F.             2019   IHC                Anti-PD-L1         Rabbit, MAB   E1L3N           1 : 200    Cell Signaling Technology, Danvers, MA, USA        Score 3
  Zhu, Y.            2018   IHC                Anti-PD-L1         Rabbit, MAB   SP142           1 : 50     Spring Bioscience, Inc., CA, USA                   5%

MAB: monoclonal antibody; IHC: immunohistochemistry; NR: not reported; PAB: polyclonal antibody.

###### 

Subgroup analysis of the prognostic value of PD-L1 in OS and DFS in CCA.

  Subgroup factors        No. of studies   No. of patients   HR (95% CI)        *p*       Effects model   Heterogeneity   
  ----------------------- ---------------- ----------------- ------------------ --------- --------------- --------------- ---------
  Overall survival                                                                                                        
   Total                  17               1982              1.58 (1.30-1.92)   \<0.001   REM             65.7            \<0.001
  Ethnicity                                                                                                               
   Caucasian              5                363               2.14 (1.52-3.02)   \<0.001   FEM             11.8            0.338
   Asian                  12               1619              1.49 (1.20-1.84)   \<0.001   REM             70.7            \<0.001
  Treatment                                                                                                               
   Surgery                16               1956              1.61 (1.32-1.95)   \<0.001   REM             67.0            \<0.001
   Nonsurgery             1                26                0.70 (0.19-2.60)   0.595     ---             ---             ---
  Tumor location                                                                                                          
   iCCA                   5                844               1.31 (0.88-1.95)   0.180     REM             76.9            0.002
   eCCA                   8                719               1.71 (1.25-2.36)   \<0.001   REM             63.1            0.008
   CCA                    4                419               1.98 (1.47-2.65)   \<0.001   FEM             44.2            0.146
  Disease-free survival                                                                                                   
   Total                  7                896               1.03 (0.68-1.55)   0.895     REM             72.6            0.001
  Ethnicity                                                                                                               
   Caucasian              1                26                1.13 (0.55-2.34)   0.742     ---             ---             ---
   Asian                  6                870               1.00 (0.62-1.61)   0.991     REM             77.2            0.001
  Treatment                                                                                                               
   Surgery                5                840               0.97 (0.56-1.69)   0.911     REM             81.7            \<0.001
   Non-surgery            2                56                1.12 (0.67-1.85)   0.667     FEM             0               0.965
  Tumor location                                                                                                          
   iCCA                   2                512               1.02 (0.36-2.92)   0.972     REM             92.2            \<0.001
   eCCA                   3                328               0\. (0.40-2.03)    0.800     REM             77.1            0.013
   CCA                    2                56                1.12 (0.67-1.85)   0.667     FEM             0               0.965

FEM: fixed-effects model; REM: random-effects model.

[^1]: Academic Editor: Michele Malaguarnera
